Analysts expect IMAB’s revenues to increase in the current year to $204.92 million.

IMAB’s POWR Ratings reflect this promising outlook. It has a “Buy” rating with an “A” for Industry Rank, and a “B” for Trade Grade, Buy & Hold Grade, and Peer Grade. It is currently ranked #39 of 240 stocks in the Medical – Pharmaceuticals industry.

Schrodinger, Inc. (SDGR - Get Rating)

SDGR designs computational software platforms for biopharmaceutical and industrial companies worldwide. It operates in two segments – software and drug discovery and has a portfolio of wholly-owned programs. SDGR began trading on the NASDAQ Global Select exchange on February 6. The company raised approximately $202 million through an initial public offering of $11.88 million shares, priced at $17 per share.

SDGR gained 84.7% on its first day of trading and gained more than 225% within 5 months to hit its all-time high of $99.50 in July, and 188.8% to date.

SDGR’s total revenue increased 29% year-over-year to $25.80 million in the third quarter ended September 30, 2020. This can be attributed to a 42% rise in software revenues. Gross profit rose 43% from the year-ago value to $15.30 million, while net income increased substantially from the negative values reported in the same period last year to $3.90 million. Moreover, SDGR has raised an additional $325.60 million through a follow-on offering over this period.

On November 23, SDGR entered a multi-year discovery collaboration with Bristol Meyers Squibb Company to develop and commercialize advanced molecule therapeutics. SDGR received $55 million in upfront payments through this partnership and is eligible to receive up to $2.70 billion for preclinical, development, and sales-based milestone payments.

The consensus EPS estimate of $0.04 for the next year indicates a 113.8% improvement year-over-year. The consensus revenue estimate of $173.50 million for 2021 indicates a 54.5% rise from the year-ago value.